Mounjaro is not available in pill form. It is an injectable medication only, delivered through a pre-filled pen that you inject under the skin once a week. That said, the landscape is shifting quickly, and there are now oral alternatives in the same drug class worth knowing about.
How Mounjaro Is Currently Taken
Mounjaro (tirzepatide) is FDA-approved exclusively as a subcutaneous injection, meaning it goes just under the skin in your abdomen, thigh, or upper arm. It comes as a single-dose pre-filled pen in six strengths, ranging from 2.5 mg up to 15 mg. You use each pen once per week, and there is no oral tablet, liquid, or any other non-injectable version of tirzepatide on the market.
The pen is designed for self-administration at home. Most people start at the lowest dose and gradually increase over several months, giving the body time to adjust and reducing the chance of nausea and other gastrointestinal side effects.
Oral GLP-1 Options That Exist Today
If needles are a dealbreaker, there are pills in the same broad drug class. Two oral options are now FDA-approved:
- Rybelsus (oral semaglutide) is a daily tablet approved for type 2 diabetes. It works on the same GLP-1 pathway as Mounjaro, though it targets only one receptor instead of two. It comes with strict dosing rules: you must take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking anything else, or taking other medications. Crushing or chewing the tablet reduces its effectiveness.
- Foundayo (orforglipron) is a newer daily pill recently approved by the FDA specifically for weight loss in adults with obesity or overweight with at least one weight-related health condition. Unlike Rybelsus, it does not need to be taken on an empty stomach, which makes the daily routine considerably simpler. You start at a low dose and increase gradually over several months.
Neither of these is the same drug as Mounjaro. They are different medications that work on overlapping but not identical pathways.
How Oral Options Compare on Weight Loss
Mounjaro’s injectable form remains the most effective option for weight loss in this class. In a head-to-head trial, people taking tirzepatide (the active ingredient in Mounjaro) lost an average of about 50 pounds over 72 weeks, compared to roughly 33 pounds for those on injectable semaglutide.
Orforglipron, the newly approved pill, produced meaningful but smaller results. In its Phase 3 trial of over 3,100 participants, the highest dose led to an average weight loss of 12.4% of body weight over 72 weeks, which translates to about 27 pounds. The lowest dose produced 7.8% loss, and a middle dose landed at 9.3%. The placebo group lost 2.1%. Side effects were similar to other GLP-1 drugs: mostly mild to moderate nausea, vomiting, and diarrhea.
So the trade-off is real. An oral pill is more convenient and eliminates the need for injections, but current pills deliver roughly half the weight loss of injectable tirzepatide at the highest doses.
Why There’s No Tirzepatide Pill
Tirzepatide is a peptide, a small protein that your digestive system would break apart before it could reach your bloodstream. That’s the fundamental challenge with turning any injectable peptide drug into a pill. Oral semaglutide (Rybelsus) gets around this with a special absorption enhancer and those strict fasting requirements, but even then, only a small fraction of the drug actually makes it into circulation.
Orforglipron takes a different approach entirely. It’s a small molecule, not a peptide, which means it survives digestion on its own without needing protective coatings or fasting windows. Eli Lilly, the company behind both Mounjaro and orforglipron, developed orforglipron as its oral strategy rather than trying to reformulate tirzepatide itself into a tablet. There is no publicly announced program to create a pill version of tirzepatide.
Choosing Between Injections and Pills
Your choice comes down to what matters most to you. If maximizing weight loss is the priority and you can tolerate a weekly injection, Mounjaro remains the strongest performer. The pre-filled pen uses a small, hidden needle that most people describe as less painful than expected, and you only deal with it once a week.
If you strongly prefer a daily pill, orforglipron (Foundayo) is now available and doesn’t require fasting or special timing around meals. Rybelsus is another option, though it’s approved for diabetes rather than weight management and comes with more restrictive dosing instructions. Your prescriber can help you weigh the practical differences, including insurance coverage and cost, which vary significantly between these medications.